Email
Mot de passe
Pour plus de facilité, laissez cette case cochée. Sur les appareils partagés, nous vous conseillons de vous déconnecter d'Euroquity à la fin de votre utilisation
Email

Vous allez recevoir un email pour créer un nouveau mot de passe

Ou connectez-vous avec votre réseau social favori

Localisation

Choisissez votre pays

et votre langue

Bonjour ,

Bienvenue sur votre profil personnel. Votre carte de visite professionnelle présente votre activité principale. Elle sera visible sur EuroQuity.

% complété

%

Inflection Biosciences Ltd_media
medal 1
Ce profil est validé par 1 label.

Company

Inflection Biosciences Ltd

Inflection Biosciences Ltd_logo
7
EQ SCORE

L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.

Inflection Biosciences is developing innovative new therapeutics for the treatment of unmet needs in cancer. Its lead program is IBL-302, a first in class, bi-specific PIM/PI3K inhibitor in pre-clinical development for breast cancer.

Dublin, Dublin, Ireland

Send a message

  • 2

    employees

  • €0

    turnover

Anglais

Inflection Biosciences Ltd Who are we?

Inflection Biosciences Ltd, based in Dublin and London, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments was licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises the IBL-300 series (PIM/PI3K/mTOR inhibitors) and IBL-202 (PIM/PI3K inhibitor) selected from a series of unique dual mechanism kinase inhibitors and the IBL-100 series (selective pan-PIM kinase inhibitors),...

See more

Inflection Biosciences Ltd, based in Dublin and London, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments was licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises the IBL-300 series (PIM/PI3K/mTOR inhibitors) and IBL-202 (PIM/PI3K inhibitor) selected from a series of unique dual mechanism kinase inhibitors and the IBL-100 series (selective pan-PIM kinase inhibitors), currently in preclinical stages of development. Data generated to date suggests potential application in a range of treatment resistant solid tumours and haematological malignancies. Inflection Biosciences was named ‘Start-up Company of the Year’ at the 2014 Irish Pharma Awards. For more information please visit www.inflectionbio.com

Our latest news

Our network

Your request has been sent
Join this network
Your message has been sent

Certifications

Seal of Excellence
The Seal of Excellence is a quality label awarded to project proposals submitted to Horizon 2020 which succeeded a highly competitive evaluation process by independent experts, but did not received funding due to budget limits. This quality label is a guarantee for investors to find high standard project proposals from European SMEs with growth potential.
786 Entities

Communities

Our history

Start in 31/12/2012

  • 31/12/2012

    Inflection Biosciences Ltd incorporated in Dublin, Ireland

  • 28/05/2013

    Cancer pipeline secure via licensing agreement with Spanish National Cancer Research Centre (CNIO)

  • 1/12/2012

    Initial seed round completed with private investor

  • 28/5/2013

    Investment secured from Irish Sovereign, Enterprise Ireland

  • 1/5/2017

    In vivo proof of concept with IBL-302 in breast, lung, AML, neuroblastoma

to be continued ...